PT - JOURNAL ARTICLE AU - Budziar, Wiktoria AU - Gembara, Katarzyna AU - Szymczak, Aleksander AU - Jędruchniewicz, Natalia AU - Baniecki, Krzysztof AU - Pikies, Aleksandra AU - Nahorecki, Artur AU - Hoffmann, Agnieszka AU - Kardaś, Amelia AU - Klimek, Tomasz AU - Kaźmierczak, Zuzanna AU - Witkiewicz, Wojciech AU - Barczyk, Kamil AU - Dąbrowska, Krystyna TI - Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021 AID - 10.1101/2021.06.22.21258711 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.22.21258711 4099 - http://medrxiv.org/content/early/2021/06/25/2021.06.22.21258711.short 4100 - http://medrxiv.org/content/early/2021/06/25/2021.06.22.21258711.full AB - Population immunity (herd immunity) to SARS-CoV-2 derives from two well-defined and controlled sources: vaccinations or diagnosed and registered cases of the disease. It may however also result from asymptomatic, oligosymptomatic, or even full-blown but undiagnosed and unregistered cases from which patients recovered at home. Here we present a population screening for SARS-CoV-2 specific IgG and IgA antibodies in Polish citizens (N=501) who had never been positively diagnosed with or vaccinated against SARS-CoV-2. Serum samples were collected in Wrocław (Lower Silesia) on 15th and 22nd May 2021. Sera from hospitalized COVID-19 patients (N=22) or from vaccinated citizens (N=14) served as positive controls.Sera were tested with Microblot-Array COVID-19 IgG and IgA (quantitative) that contain specific SARS-CoV-2 antigens: NCP, RBD, Spike S2, E, ACE2, PLPro protein, and antigens for exclusion cross-reactivity with other coronaviruses: MERS-CoV, SARS-CoV, HCoV 229E Np, HCoV NL63 Np.Within the investigated population of healthy individuals who had never been positively diagnosed with or vaccinated against SARS-CoV-2, we found that 35.5% (178 out of 501) were positive for SARS-CoV-2-specific IgG and 52.3% (262 out of 501) were positive for SARS-CoV-2-specific IgA; 21.2% of the investigated population developed virus-specific IgG or IgA while being asymptomatic. Anti-RBD IgG, which represents virus-neutralizing potential, was found in 25.6% of individuals (128 out of 501).These patients, though positive for anti-SARS-CoV-2 antibodies, cannot be identified in the public health system as convalescents due to undiagnosed infections, and they are considered unaffected by SARS-CoV-2. Their contribution to population immunity against COVID-19 should however be considered in predictions and modeling of the COVID-19 pandemic. Of note, the majority of the investigated population still lacked anti-RBD IgG protection (74.4%); thus vaccination against COVID-19 is still of the most importance for controlling the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Research and Development Center in Poland, grant no. SZPITALEJEDNOIMIENNE/48/2020Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The experiments were approved by the local Commission of Bioethics of the Regional Specialist Hospital in Wrocław (approval number: KB/02/2020, policy No. COR193657).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe provide raw data applicable for any further analysis as the supplementary material